Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus MICONAZOLE 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus MICONAZOLE 7.
AMPHOTEC vs MICONAZOLE 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (~50%) and renal (~<1% unchanged)
Category C
Category A/B
Antifungal
Antifungal